"EntreMed investors should realize that the company may be more about keeping itself in business by being a research company than in actually bringing products to market. Is this an unreasonalbe thought or fear on my part?"
The thoughts and fears you express are pretty unreasonable.
Hey, what exactly would you expect a clinical stage biopharmaceutical company to look like? Ten years ago, Celgene was a company holding nothing better than an orphan drug approval for Thalidomide to treat leprosy. Not to demean leprosy patients, but there just aren't enough of them to make that business very interesting to anybody.
A "research" company... is that like when there's some key guy with a big ego telling you how smart he is and how great his discoveries are going to be for all mankind (please point out a press release that suggests ENMD has anybody like that on the payroll)? Only an idiot could look at a list of 14 active ongoing trials and conclude that the company is not actively trying to bring drugs to market. See, research is in a lab somewhere, not out there in the clinic with real patients, and real patients have real doctors who will publish real results for all the world to read. All that would be a huge risk for a "research company."
Celgene is a stockholder and a partner. Entremed success is to their benefit. Thanks in part to Celgene's investments in Entremed, Panzem research continues to proceed. There's no evidence of Celgene or anyone else stalling anything.
Helpwanted, it's possible that you're an intelligent fellow, but your Fears, Uncertainties, and Doubts are in conflict with that hypothesis unless you're here with a disingenuous agenda.
AI
Market Data 
Markets 
